Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousands).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The main reason for the improvement in operating profit was a timing shift, whereby multiple large projects in the CRO business for which revenue recognition had been expected during the previous fiscal year slipped into the current interim period. The shift of expenses in the TR business into the second half was also a factor. Increased orders in the CRO business were mainly driven by increased orders from customers in Europe and North America.
Not applicable
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥17,568 millions (YoY +19.0%) |
| Operating profit | ¥1,555 millions |
| Ordinary income | ¥3,081 millions (YoY +89.3%) |
| Profit attributable to owners of the parent | ¥2,197 millions (YoY +107.1%) |
| Net income per share | ¥52.79 |
| Equity ratio | End of the current fiscal period 36.1 / End of previous period 41 |
| Total assets | ¥109,364 millions |
| Net assets | ¥39,818 millions |
| Cash flows from operating activities | ¥5,607,346 thousands |
| Cash flows from investing activities | ¥-5,485,200 thousands |
| Cash flows from financing activities | ¥5,922,911 thousands |
| Cash and cash equivalents at end of period | ¥24,270,933 thousands |
| Full-year earnings forecast | Net Sales ¥38,000 millions (YoY +16.8%) / Operating profit ¥3,000 millions (YoY +13.0%) / Ordinary income ¥6,000 millions (YoY +2.9%) / Net income ¥3,500 millions (YoY -23.4%) |
| Annual Dividend Forecast | ¥50 → ¥50（0.0%） |
| Segment revenue | CRO Business ¥16,915,628 thousands (YoY +19.7%), Translational Research business ¥90,674 thousands (YoY +222.3%), Medipolis Business ¥325,636 thousands (YoY -4.6%), U.S. Real Estate ¥97,952 thousands (YoY +11.3%) |
| Segment profit | CRO Business ¥4,009,980 thousands (YoY +81.7%), Translational Research business ¥-2,097,697 thousands, Medipolis Business ¥-70,330 thousands, U.S. Real Estate ¥-68,152 thousands |
| Orders received and order backlog | Orders received ¥19,641 millions / Order backlog ¥43,784 millions |
| Depreciation and amortization | ¥1,605,377 thousands |
| Impairment loss | ¥7,995 thousands |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥2,017 thousands, Other ¥5 thousands / Extraordinary loss Loss on disposal of non-current assets ¥83,775 thousands, Impairment Losses ¥7,995 thousands |
| Disclosure regarding the going concern assumption | Not applicable |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement None |
| Changes in the scope of consolidation | 0 new companies, 0 excluded companies. No applicable items. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for analysts and institutional investors) |
| Issued Shares at Period-End | 41,632,400 |
| Treasury Shares at Period-End | 586 |
| Factors Behind Changes in Business Performance | The main reason for the improvement in operating profit was a timing shift, whereby multiple large projects in the CRO business for which revenue recognition had been expected during the previous fiscal year slipped into the current interim period. The shift of expenses in the TR business into the second half was also a factor. Increased orders in the CRO business were mainly driven by increased orders from customers in Europe and North America. |
Items this document does not state (6)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The main reason for the improvement in operating profit was a timing shift, whereby multiple large projects in the CRO business for which revenue recognition had been expected during the previous fiscal year slipped into the current interim period. The shift of expenses in the TR business into the second half was also cited as a factor.